Filing Details

Accession Number:
0001127602-21-017369
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-05-19 16:04:09
Reporting Period:
2021-05-18
Accepted Time:
2021-05-19 16:04:09
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1492422 Apellis Pharmaceuticals Inc. APLS Pharmaceutical Preparations (2834) 271537290
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1856078 Jeffrey Mark Delong C/O Apellis Pharmaceuticals, Inc.
100 Fifth Avenue, 3Rd Floor
Waltham MA 02451
Senior Vice President No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-05-18 2,000 $15.52 11,490 No 4 M Direct
Common Stock Disposition 2021-05-18 2,000 $55.00 9,490 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2021-05-18 2,000 $0.00 2,000 $15.52
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
48,000 2028-02-04 No 4 M Direct
Footnotes
  1. This is a scheduled exercise from an established 10B5-1 trading plan.
  2. This amount includes 792 shares from 04/30/2021 ESPP purchase.
  3. This stock option will vest as to 25% of the shares underlying the options on the first anniversary of the grant date, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.